Cencora (COR)

Drugs • Health Care

Stock AI

News & Reports

July 01, 2026 Cencora Sets Stage for Third Quarter Fiscal 2026 Earnings Release Cencora, Inc. has announced its Q3 2026 earnings release set for August 5, 2026, before market opening. A conference call will follow at 8:30 a.m. ET for detailed insights.

June 15, 2026 Cencora Welcomes Samantha Hammock as New Chief Human Resources Officer Cencora has appointed Samantha Hammock as the new Chief Human Resources Officer, succeeding Silvana Battaglia, who is retiring after seven years. Hammock, with extensive experience from Verizon and American Express, aims to advance Cencora's workforce transformation and strengthen its culture as the company continues to grow in the pharmaceutical sector.

May 27, 2026 Cencora Appoints Eva Boratto as New CFO Amid Strategic Growth Plans Cencora has appointed Eva C. Boratto as its new CFO, succeeding James F. Cleary. With extensive experience in finance, Boratto is set to lead Cencora's strategic growth in the pharmaceutical sector while maintaining strong financial performance.

May 21, 2026 Cencora Updates Fiscal Year 2026 Financial Outlook Amid Strategic Share Repurchases Cencora, Inc. has updated its fiscal year 2026 earnings guidance to reflect enhanced EPS expectations due to strategic share repurchases. The company has authorized a new $2 billion share buyback program, signaling confidence in its long-term growth and commitment to shareholder value.

May 08, 2026 Cencora Faces Securities Fraud Investigation Following Disappointing Q2 Results Cencora, Inc. is under investigation for potential securities fraud following disappointing Q2 results that missed revenue expectations. The company's stock has plummeted, prompting legal scrutiny and calls for affected investors to come forward.

May 06, 2026 Cencora's Q2 2026 Report: Growth Amid Strategic Acquisitions Cencora's Q2 2026 report showcases a revenue increase of 3.8%, driven by key acquisitions and operational improvements. The company's focus on oncology and international growth positions it well for future challenges.

May 06, 2026 Cencora Reports Strong Fiscal 2026 Second Quarter Results Cencora, Inc. reported a solid performance in Q2 2026, with revenues increasing 3.8% to $78.4 billion and diluted EPS rising to $8.40. The company also updated its fiscal outlook, reflecting strong operational performance and confidence in future growth.

April 01, 2026 Cencora Sets the Stage for Second Quarter Earnings Report Cencora, Inc. is set to release its Q2 2026 earnings on May 6, 2026, before market opening. The conference call will feature executives sharing insights on the company's performance and strategic direction.

March 23, 2026 Cencora to Strengthen Retina Care with EyeSouth Partners Acquisition Cencora, Inc. has announced the acquisition of EyeSouth Partners' retina business for $1.1 billion, aiming to enhance its Retina Consultants of America network. This strategic move is expected to improve patient care quality and expand access to innovative treatments, reaffirming Cencora's commitment to advancing ophthalmology services.

March 17, 2026 Cencora Announces Financial Leadership Transition Cencora, Inc. has announced the retirement of CFO James F. Cleary, effective June 30, 2026, after a successful tenure that enhanced shareholder value. The company is implementing an executive search for his successor while reaffirming its earnings guidance for 2026.

February 18, 2026 Cencora and Covetrus Announce Strategic Merger to Enhance Animal Health Sector Cencora and Covetrus have announced a strategic merger to create a comprehensive platform for animal healthcare, enhancing access and operational efficiencies. The $3.5 billion deal aims to empower veterinary practices and support innovative solutions for better animal care.

February 13, 2026 Cencora Secures $3.0 Billion in Senior Notes Offering Cencora, Inc. has successfully closed a $3 billion offering of senior notes to bolster its financial position and fund strategic initiatives. The proceeds will primarily repay credit agreements related to recent acquisitions, reflecting the company's strong growth trajectory in the pharmaceutical industry.

February 10, 2026 Cencora Secures $3.5 Billion Through Senior Notes Offering Cencora, Inc. has successfully priced $3.5 billion in senior notes to enhance its financial stability and facilitate the acquisition of OneOncology. Proceeds will primarily be used for debt repayment and corporate purposes, further solidifying Cencora's market position.

February 04, 2026 Cencora Reports Strong First Quarter Results for Fiscal 2026 Cencora, Inc. reported a 5.5% revenue increase for Q1 2026, reaching $85.9 billion. The company's diluted EPS rose to $2.87, and it recently acquired OneOncology to strengthen its healthcare services. Cencora also updated its fiscal guidance, signaling continued growth potential.

February 04, 2026 Cencora Reports Strong Q1 2026 Results Amid Strategic Reorganization and Major Acquisition Cencora, Inc. reported a 5.5% revenue increase to $85.93 billion in Q1 2026, driven by a new reporting structure and the acquisition of OneOncology. Despite rising operating expenses, the company is well-positioned for continued growth in the pharmaceutical sector.

January 22, 2026 Cencora Strengthens Board with Appointment of Ellen Cooper Cencora, Inc. has appointed Ellen Cooper as an independent director, effective January 20, 2026. With her extensive background in risk management and leadership in the insurance sector, Cooper's election is expected to strengthen Cencora's governance and strategic direction in the healthcare market.

January 06, 2026 Cencora Sets Stage for First Quarter Fiscal 2026 Earnings Release Cencora, Inc. is set to announce its Q1 Fiscal 2026 earnings on February 4, 2026. A conference call will follow to discuss the results, featuring key executives. Investors can access the call via webcast or telephone.

December 15, 2025 Cencora Accelerates OneOncology Acquisition, Expanding Community Oncology Solutions Cencora, Inc. is set to acquire OneOncology for $7.4 billion, aiming to boost community oncology solutions. This strategic move supports independent practices while enhancing patient access to care.

November 25, 2025 Cencora's 2025 Annual Report: Growth and Strategic Restructuring Cencora's 2025 annual report reveals a total revenue of $321.3 billion, driven by growth in U.S. and international segments. The report highlights strategic restructuring and effective financial management despite challenges.

November 05, 2025 Cencora Reports Fiscal 2025 Fourth Quarter and Year-End Results: A Year of Growth Amid Challenges Cencora's fiscal 2025 results highlight a 5.9% revenue increase to $83.7 billion, despite facing profitability challenges with a GAAP EPS of $(1.75). The company's strategic initiatives, including acquisitions and digital transformation, position it for future growth in the pharmaceutical distribution sector.

October 06, 2025 Cencora Set to Release Q4 Fiscal 2025 Earnings: Key Details Announced Cencora, Inc. will release its Q4 Fiscal 2025 earnings on November 5, 2025, followed by a conference call at 8:30 a.m. ET. Investors can access the call via webcast or telephone for insights on the company's financial performance.

August 06, 2025 Cencora's Q3 2025 Report: A Strong Performance Amid Challenges Cencora's Q3 2025 report reveals an 8.7% revenue growth to $80.66 billion, driven by U.S. Healthcare Solutions and strategic acquisitions. Despite challenges, the company maintains a strong financial position and promising outlook.

May 07, 2025 Cencora Reports Strong Q2 2025 Financial Results Amid Strategic Acquisition Cencora, Inc. announced impressive Q2 2025 financials with a revenue boost to $7 billion, thanks to its U.S. Healthcare Solutions segment. The strategic acquisition of Retina Consultants of America promises to strengthen its market position and operational capabilities.

May 07, 2025 Cencora Reports Strong Second Quarter Results for Fiscal Year 2025 Cencora, Inc. reported significant financial growth for Q2 FY 2025, with revenues of $75.5 billion and an EPS increase to $3.68. The company also raised its adjusted EPS outlook, showcasing confidence in its continued success in the healthcare sector.

March 28, 2025 Cencora Set to Release Second Quarter Fiscal 2025 Earnings: Key Details Announced Cencora, Inc. is set to release its financial results for Q2 2025 on May 7. A conference call will follow to discuss the results and future strategies. Investors can access the call via webcast or phone.

February 06, 2025 Cencora Announces Strategic Share Repurchase from Walgreens Boots Alliance Cencora, Inc. has initiated a $50 million share repurchase from Walgreens Boots Alliance, reflecting its commitment to enhancing shareholder value. This strategic move aims to consolidate ownership and potentially improve market valuation as Cencora navigates its growth in the pharmaceutical sector.

February 05, 2025 Cencora's Q1 2025 Report: A Strategic Acquisition and Robust Revenue Growth Cencora, Inc. reports a $9.2 billion revenue increase in Q1 2025, driven by its recent acquisition of Retina Consultants of America. The company aims for sustained growth despite rising operational costs and cash flow challenges.

February 05, 2025 Cencora Reports Strong Q1 Results for Fiscal 2025 Cencora, Inc. reported a robust 12.8% year-over-year revenue growth in Q1 2025, reaching $81.5 billion. Despite a decline in GAAP EPS, adjusted EPS rose significantly, reflecting strong operational performance. The company also revised its EPS guidance upward, bolstered by strategic acquisitions.

January 30, 2025 SWOT Analysis of Cencora in 2025 This SWOT analysis of Cencora, Inc. in 2025 reveals its competitive strengths, operational weaknesses, and potential growth opportunities amid industry threats. The company is well-positioned but must strategically navigate challenges to capitalize on market growth.

November 26, 2024 Cencora's 2024 Annual Report: A Year of Growth, Challenges, and Strategic Acquisitions Cencora's 2024 Annual Report reveals a strong revenue growth of $293.9 billion, driven by its U.S. Healthcare Solutions. Despite facing opioid-related litigation, the company expands through strategic acquisitions, including Retina Consultants of America.

July 31, 2024 Cencora's Q3 2024 Financial Report: A Strong Performance Amidst Challenges Cencora, Inc. reported a revenue increase to $74.24 billion in Q3 2024, reflecting a 10.9% growth year-over-year. Despite facing geopolitical tensions and economic challenges, the company demonstrated resilience through strategic investments and a solid balance sheet.

May 01, 2024 Cencora Reports Strong Q2 2024 Financials: Revenue Growth and Strategic Investments Drive Performance Cencora, Inc. has reported a robust revenue increase to $68.41 billion in Q2 2024, driven by its U.S. Healthcare Solutions segment. Despite rising operating expenses, the company is strategically investing in acquisitions and shareholder returns, positioning itself for continued success in the pharmaceutical market.

SWOT Analysis of Cencora in 2025

Last updated: January 30, 2025

This SWOT analysis provides an overview of Cencora, Inc., evaluating its strengths, weaknesses, opportunities, and threats as of 2025. Cencora, a leading global pharmaceutical sourcing and distribution services company, is positioned to navigate the complexities of the healthcare landscape while facing inherent challenges.

Strengths

Established and efficient distribution network providing competitive advantage.
Strong market leadership with a substantial share in the pharmaceutical distribution sector.
Diverse service offerings including logistics, consulting, and patient advisory services.
Robust relationships with major customers, enhancing revenue stability.
Regulatory expertise creating barriers for new entrants.

Weaknesses

High dependency on a limited number of key customers, increasing financial vulnerability.
Challenges in realizing strategic benefits from partnerships, particularly with WBA.
Complex integration processes for recent acquisitions can disrupt operations.
Potential operational risks associated with distribution and logistics management.

Opportunities

Rapid growth in the pharmaceutical sector, particularly with an aging population.
Expansion of international markets presents new revenue streams.
Increasing demand for generics and biosimilars as patents expire.
Innovations in biotechnology and drug therapies offer avenues for new service offerings.
Regulatory changes may create opportunities for enhanced compliance services.

Threats

Intense competition and industry consolidation may pressure margins.
Regulatory compliance challenges could lead to operational disruptions.
Economic volatility affecting consumer spending and credit risks.
Ongoing litigation and liability risks, particularly related to opioid distribution.
Global geopolitical tensions impacting international operations and costs.

In conclusion, Cencora stands at a critical juncture in 2025, characterized by strong market positioning and operational strengths. However, it must navigate significant weaknesses and external threats while capitalizing on myriad opportunities within the growing pharmaceutical landscape. Strategic focus on innovation and customer relationships will be essential for sustained growth and resilience.

You may also be interested in: